Progenics Pharmaceuticals Inc Conference Call to Discuss Topline Results from Phase 2b Trial of AZEDRA
Conference Call Progenics Pharmaceuticals Inc
Progenics Pharmaceuticals Inc Conference call or earnings call will be held on Mar 30, 2017 During the earnings conference call's session Progenics Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Progenics Pharmaceuticals Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
Progenics Pharmaceuticals, Inc., a Delaware corporation incorporated in 1986, develops innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer (AZEDRA, 1095 and PSMA ADC), and imaging agents (1404 and PyL) intended to enable clinicians and patients to accurately visualize and manage their disease. In late 2015 Progenics acquired EXINI Diagnostics AB, in order to obtain know-how and expertise for the development of imaging analysis tools and solutions. As a result of that transaction, Progenics also acquired the EXINI Bone BSI bone scan index product. EXINI Bone BSI, which is approved for use in Europe, Japan and the U.S. (though not yet available in the U.S.), is an analytical tool enabling health care professionals to quantify the results of bone scan images.Read more Conference Call